p35/cyclin-dependent kinase 5 is required for protection against β-amyloid-induced cell death but not tau phosphorylation by ceramide

Journal of Molecular Neuroscience

Volumn 31, Issue 1, 2007, Pages 23-35

  Seyb, Kathleen I ^a   Ansar, Sabah ^a   Li, Guibin ^a   Bean, Jennifer ^a   Michaelis, Mary L ^a   Dobrowsky, Rick T ^a  

^a UNIVERSITY OF KANSAS   (United States)

Author keywords

amyloid; Alzheimer's disease; Calpain; Ceramide; Cortical neurons; Cyclin dependent kinase 5; Glycogen synthase kinase 3 ; p35; Tau

Indexed keywords

AMYLOID BETA PROTEIN; CALPAIN; CERAMIDE; CYCLIN DEPENDENT KINASE 5; GLYCOGEN SYNTHASE KINASE 3BETA; PROTEIN P39; REGULATOR PROTEIN; TAU PROTEIN;

ANIMAL CELL; ARTICLE; BRAIN NERVE CELL; CELL ISOLATION; CONTROLLED STUDY; DRUG MECHANISM; EMBRYO; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; FETUS; KNOCKOUT MOUSE; MOUSE; NERVE CELL NECROSIS; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; WILD TYPE;

AMYLOID BETA-PROTEIN; ANIMALS; CALPAIN; CELL DEATH; CELLS, CULTURED; CERAMIDES; CEREBRAL CORTEX; CYCLIN-DEPENDENT KINASE 5; ENZYME ACTIVATION; GLYCOGEN SYNTHASE KINASE 3; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NERVE TISSUE PROTEINS; NEURONS; PHOSPHORYLATION; TAU PROTEINS;

MUS;

EID: 34247093357     PISSN: 08958696     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02686115     Document Type: Article

References (68)

1. Ayasolla K., Khan M., Singh A. K., and Singh I. (2004) Inflammatory mediator and beta-amyloid (25-35)-induced ceramide generation and iNOS expression are inhibited by vitamin E. Free Radic. Biol. Med. 37, 325-338.
2. Billingsley M. L. and Kincaid R. L. (1997) Regulated phosphorylation and dephosphorylation of tau protein: effects on microtubule interaction, intracellular trafficking and neurodegeneration. Biochem. J. 323, 577-591.
3. Boland B. and Campbell V. (2003) β-Amyloid (1-40)-induced apoptosis of cultured cortical neurones involves calpain-mediated cleavage of poly-ADP-ribose polymerase. Neurobiol. Aging 24, 179-186.
4. Brann A. B., Scott R., Neuberger Y., Abulafia D., Boldin S., Fainzilber M., and Futerman A. H. (1999) Ceramide signaling downstream of the p75 neurotrophin receptor mediates the effects of nerve growth factor on outgrowth of cultured hippocampal neurons. J. Neurosci. 19, 8199-8206.
5. Bu B., Klunemann H., Suzuki K., Li J., Bird T., Jin L. W., and Vincent I. (2002) Niemann-Pick disease type C yields possible clue for why cerebellar neurons do not form neurofibrillary tangles. Neurobiol. Dis. 11, 285-297.
6. Bu B., Li J., Davies P., and Vincent I. (2002) Deregulation of cdk5, hyperphosphorylation, and cytoskeletal pathology in the Niemann-Pick type C murine model. J. Neurosci. 22, 6515-6525.
7. Cai X. H., Tomizawa K., Tang D., Lu Y. F., Moriwaki A., Tokuda M., et al. (1997) Changes in the expression of novel Cdk5 activator messenger RNA (p39nck5ai mRNA) during rat brain development. Neurosci. Res. 28, 355-360.
8. Casaccia-Bonnefil P., Carter B. D., Dobrowsky R. T., and Chao M. V. (1996) Death of oligodendrocytes mediated by the interaction of nerve growth factor with its receptor p75. Nature 383, 716-719.
9. Chae T., Kwon Y. T., Bronson R., Dikkes P., Li E., and Tsai L. H. (1997) Mice lacking p35, a neuronal specific activator of Cdk5, display cortical lamination defects, seizures, and adult lethality. Neuron 18, 29-42.
10. Courtney M. J., Akerman K. E., and Coffey E. T. (1997) Neurotrophins protect cultured cerebellar granule neurons against the early phase of cell death by a two-component mechanism. J. Neurosci. 17, 4201-4211.
11. Cruz J. C., Tseng H. C., Goldman J. A., Shih H., and Tsai L. H. (2003) Aberrant Cdk5 activation by p25 triggers pathological events leading to neurodegeneration and neurofibrillary tangles. Neuron 40, 471-483.
12. Cutler R. G., Kelly J., Storie K., Pedersen W. A., Tammara A., Hatanpaa K., et al. (2004) Involvement of oxidative stress-induced abnormalities in ceramide and cholesterol metabolism in brain aging and Alzheimer's disease. Proc. Natl. Acad. Sci. U. S. A. 101, 2070-2075.
13. Drouet B., Fifre A., Pincon-Raymond M., Vandekerckhove J., Rosseneu M., Gueant J. L., et al. (2001) ApoE protects cortical neurones against neurotoxicity induced by the non-fibrillar C-terminal domain of the amyloid-beta peptide. J. Neurochem. 76, 117-127.
14. Furuya S., Mitoma J., Makino A., and Hirabayashi Y. (1998) Ceramide and its interconvertible metabolite sphingosine function as indispensable lipid factors involved in survival and dendritic differentiation of cerebellar Purkinje cells. J. Neurochem. 71, 366-377.
15. Glenner G. G. and Wong C. W. (1984) Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem. Biophys. Res. Commun. 120, 885-890.
16. Goedert M., Crowther R. A., and Spillantini M. G. (1998) Tau mutations cause frontotemporal dementias. Neuron 21, 955-958.
17. Goedert M., Jakes R., Spillantini M. G., Crowther R. A., Cohen P., Vanmechelen E., et al. (1995) Tau protein in Alzheimer's disease. Biochem. Soc. Trans. 23, 80-85.
18. Goodman Y. and Mattson M. P. (1996) Ceramide protects hippocampal neurons against excitotoxic and oxidative insults, and amyloid peptide toxicity. J. Neurochem. 66, 869-872.
19. Grundke-Iqbal I., Iqbal K., Quinlan M., Tung Y. C., Zaidi M. S., and Wisniewski H. M. (1986) Microtubule-associated protein tau. A component of Alzheimer paired helical filaments. J. Biol. Chem. 261, 6084-6089.
20. Hallows J. L., Chen K., DePinho R. A., and Vincent I. (2003) Decreased cyclin-dependent kinase 5 (cdk5) activity is accompanied by redistribution of cdk5 and cytoskeletal proteins and increased cytoskeletal protein phosphorylation in p35 null mice. J. Neurosci. 23, 10,633-10,644.
21. Hallows J. L., Iosif R. E., Biasell R. D., and Vincent I. (2006) p35/p25 is not essential for tau and cytoskeletal pathology or neuronal loss in Niemann-Pick type C disease. J. Neurosci. 26(10), 2738-2744.
22. Hamdane M., Sambo A. V., Delobel P., Begard S., Violleau A., Delacourte A., et al. (2003) Mitotic-like tau phosphorylation by p25-Cdk5 kinase complex. J. Biol. Chem. 278, 34,026-34,034.
23. Hartfield P. J., Bilney A. J., and Murray A. W. (1998) The role of c-Jun N-terminal kinase activation in ceramide-induced apoptosis in PC12 cells. Biochem. Soc. Trans. 26, S327.
24. Hashiguchi M., Saito T., Hisanaga S., and Hashiguchi T. (2002) Truncation of CDK5 activator p35 induces intensive phosphorylation of Ser202/Thr205 of human tau. J. Biol. Chem. 277, 44,525-44,530.
25. Hellmich M. R., Pant H. C., Wada E., and Battey J. F. (1992) Neuronal cdc2-like kinase: a cdc2-related protein kinase with predominantly neuronal expression. Proc. Natl. Acad. Sci. U. S. A. 89, 10,867-10,871.
26. Howlett D. R., Jennings K. H., Lee D. C., Clark M. S., Brown F., Wetzel R., et al. (1995) Aggregation state and neurotoxic properties of Alzheimer beta-amyloid peptide. Neurodegeneration 4, 23-32.
27. Humbert S., Lanier L. M., and Tsai L. H. (2000) Synaptic localization of p39, a neuronal activator of cdk5. Neuroreport 11, 2213-2216.
28. Ito A. and Horigome K. (1995) Ceramide prevents neuronal programmed cell death induced by nerve growth factor deprivation. J. Neurochem. 65, 463-466.
29. Jana A. and Pahan K. (2004) Fibrillar amyloid-beta peptides kill human primary neurons via NADPH oxidase-mediated activation of neutral sphingomyelinase. Implications for Alzheimer's disease. J. Biol. Chem. 279, 51,451-51,459.
30. Kawahara M. and Kuroda Y. (2000) Molecular mechanism of neurodegeneration induced by Alzheimer's beta-amyloid protein: channel formation and disruption of calcium homeostasis. Brain Res. Bull. 53, 389-397.
31. Kesavapany S., Lau K. F., Ackerley S., Banner S. J., Shemilt S. J., Cooper J. D., et al. (2003) Identification of a novel, membrane-associated neuronal kinase, cyclin-dependent kinase 5/p35-regulated kinase. J. Neurosci. 23,4975-4983.
32. Kesavapany S., Lau K. F., McLoughlin D. M., Brownlees J., Ackerley S., Leigh P. N., et al. (2001) p35/cdk5 binds and phosphorylates beta-catenin and regulates beta-catenin/presenilin-1 interaction. Eur. J. Neurosci. 13, 241-247.
33. Ko J., Humbert S., Bronson R. T., Takahashi S., Kulkarni A. B., Li E., and Tsai L. H. (2001) p35 and p39 are essential for cyclin-dependent kinase 5 function during neurodevelopment. J. Neurosci. 21, 6758-6771.
34. Kuroda Y., Kobayashi K., Ichikawa M., Kawahara M., and Muramoto K. (1995) Application of long-term cultured neurons in aging and neurological research: aluminum neurotoxicity, synaptic degeneration and Alzheimer's disease. Gerontology 41, 2-6.
35. Ledee D. R., Gao C. Y., Seth R., Fariss R. N., Tripathi B. K., and Zelenka P. S. (2005) A specific interaction between Muskelin and the cyclin-dependent kinase 5 activator p39 promotes peripheral localization of Muskelin. J. Biol. Chem. 280, 21,376-21,383.
36. Lee J. T., Xu J., Lee J. M., Ku G., Han X., Yang D. I., et al. (2004) Amyloid-beta peptide induces oligodendrocyte death by activating the neutral sphingomyelinase-ceramide pathway. J. Cell Biol. 164, 123-131.
37. Lee M. S. and Tsai L. H. (2003) Cdk5: one of the links between senile plaques and neurofibrillary tangles? J. Alzheimers Disease 5, 127-137.
38. Lee M. S., Kwon Y. T., Li M., Peng J., Friedlander R. M., and Tsai L. H. (2000) Neurotoxicity induces cleavage of p35 to p25 by calpain. Nature 405, 360-364.
39. Li G., Faibushevich A., Turunen B. J., Yoon S. O., Georg G., Michaelis M. L., and Dobrowsky R. T. (2003) Stabilization of the cyclin-dependent kinase 5 activator, p35, by paclitaxel decreases beta-amyloid toxicity in cortical neurons. J. Neurochem. 84, 347-362.
40. Lilja L., Johansson J. U., Gromada J., Mandic S. A., Fried G., Berggren P. O., and Bark C. (2004) Cyclin-dependent kinase 5 associated with p39 promotes Munc18-1 phosphorylation and Ca(2+)-dependent exocytosis. J. Biol. Chem. 279, 29,534-29,541.
41. Lovestone S., Reynolds C. H., Latimer D., Davis D. R., Anderton B. H., Gallo J. M., et al. (1994) Alzheimer's disease-like phosphorylation of the microtubule-associated protein tau by glycogen synthase kinase-3 in transfected mammalian cells. Curr. Biol. 4, 1077-1086.
42. Luberto C., Kraveka J. M., and Hannun Y. A. (2002) Ceramide regulation of apoptosis versus differentiation: a walk on a fine line. Lessons from neurobiology. Neurochem. Res. 27, 609-617.
43. Manelli A. M. and Puttfarcken P. S. (1995) β-Amyloid-induced toxicity in rat hippocampal cells: in vitro evidence for the involvement of free radicals. Brain Res. Bull. 38, 569-576.
44. Mattson M. P., Cheng B., Davis D., Bryant K., Lieberburg I., and Rydel R. E. (1992) β-Amyloid peptides destabilize calcium homeostasis and render human cortical neurons vulnerable to excitotoxicity. J. Neurosci. 12, 376-389.
45. McCollum A. T. and Estus S. (2004) NGF acts via p75 low-affinity neurotrophin receptor and calpain inhibition to reduce UV neurotoxicity. J. Neurosci. Res. 77, 552-564.
46. Michaelis M. L., Ansar S., Chen Y., Reiff E. R., Seyb K. I., Himes R. H., et al. (2005) β-Amyloid-induced neurodegeneration and protection by structurally diverse microtubule-stabilizing agents. J. Pharmacol. Exp. Ther. 312, 659-668.
47. Michaelis M. L., Dobrowsky R. T., and Li G. (2002) Tau neurofibrillary pathology and microtubule stability. J. Mol. Neurosci. 19, 289-293.
48. Michaelis M. L., Ranciat N., Chen Y., Bechtel M., Ragan R., Hepperle M., et al. (1998) Protection against beta-amyloid toxicity in primary neurons by paclitaxel (Taxol). J. Neurochem. 70, 1623-1627.
49. Ohshima T., Ward J. M., Huh C. G., Longenecker G., Veeranna, Pant H. C., et al. (1996) Targeted disruption of the cyclin-dependent kinase 5 gene results in abnormal corticogenesis, neuronal pathology and perinatal death. Proc. Natl. Acad. Sci. U. S. A. 93, 11,173-11,178.
50. Patrick G. N., Zukerberg L., Nikolic M., de la Monte S., Dikkes P., and Tsai L. H. (1999) Conversion of p35 to p25 deregulates Cdk5 activity and promotes neurodegeneration. Nature 402, 615-622.
51. Patzke H. and Tsai L. H. (2002) Calpain-mediated cleavage of the cyclin-dependent kinase-5 activator p39 to p29. J. Biol. Chem. 277, 8054-8060.
52. -/- brain phenotype by low expression of a neuronal-specific enolase p25 transgene. J. Neurosci. 23, 2769-2778.
53. Posse de Chaves E., Bussiere M., MacInnis B., Vance D. E., Campenot R. B., Vance J. E. (2001) Ceramide inhibits axonal growth and nerve growth factor uptake without compromising the viability of sympathetic neurons. J. Biol. Chem. 276, 36,207-36,214.
54. Rizo J. and Sudhof T. C. (2002) Snares and Munc18 in synaptic vesicle fusion. Nat. Rev. Neurosci. 3, 641-653.
55. Song M. S. and Posse de Chaves E. I. (2003) Inhibition of rat sympathetic neuron apoptosis by ceramide. Role of p75NTR in ceramide generation. Neuropharmacology 45, 1130-1150.
56. Spillantini M. G., Murrell J. R., Goedert M., Farlow M. R., Klug A., and Ghetti B. (1998) Mutation in the tau gene in familial multiple system tauopathy with presenile dementia. Proc. Natl. Acad. Sci. U. S. A. 95, 7737-7741.
57. Takahashi S., Saito T., Hisanaga S., Pant H. C., and Kulkarni A. B. (2003. Tau phosphorylation by cyclin-dependent kinase 5/p39 during brain development reduces its affinity for microtubules. J. Biol. Chem. 278, 10,506-10,515.
58. Takashima A., Murayama M., Yasutake K., Takahashi H., Yokoyama M., and Ishiguro K. (2001) Involvement of cyclin dependent kinase5 activator p25 on tau phosphorylation in mouse brain. Neurosci. Lett. 306, 37-40.
59. Tomizawa K., Ohta J., Matsushita M., Moriwaki A., Li S. T., Takei K., and Matsui H. (2002) Cdk5/p35 regulates neurotransmitter release through phosphorylation and downregulation of P/Q-type voltage-dependent calcium channel activity. J. Neurosci. 22, 2590-2597.
60. Town T., Zolton J., Shaffner R., Schnell B., Crescentini R., Wu Y., et al. (2002) p35/Cdk5 pathway mediates soluble amyloid-beta peptide-induced tau phosphorylation in vitro. J. Neurosci. Res. 69, 362-372.
61. Tsai L. H., Delalle I., Caviness V. S. Jr., Chae T., and Harlow E. (1994) p35 is a neural-specific regulatory subunit of cyclin-dependent kinase 5. Nature 371, 419-423.
62. Tsai L. H., Takahashi T., Caviness V. S. Jr., and Harlow E. (1993) Activity and expression pattern of cyclin-dependent kinase 5 in the embryonic mouse nervous system. Development 119, 1029-1040.
63. Verhage M., Maia A. S., Plomp J. J., Brussaard A. B., Heeroma J. H., Vermeer H., et al. (2000) Synaptic assembly of the brain in the absence of neurotransmitter secretion. Science 287, 864-869.
64. Wu D. C., Yu Y. P., Lee N. T., Yu A. C., Wang J. H., and Han Y. F. (2000) The expression of Cdk5, p35, p39, and Cdk5 kinase activity in developing, adult, and aged rat brains. Neurochem. Res. 25, 923-929.
65. Yankner B. A , Dawes L. R., Fisher S., Villa-Komaroff L., Oster-Granite M. L., and Neve R. L. (1989) Neurotoxicity of a fragment of the amyloid precursor associated with Alzheimer's disease. Science 245, 417-420.
66. Zaidi A., Barron L., Sharov V. S., Schoneich C., Michaelis E. K., and Michaelis M. L. (2003) Oxidative inactivation of purified plasma membrane Ca2+-ATPase by hydrogen peroxide and protection by calmodulin. Biochemistry 42, 12,001-12,010.
67. Zhang M., Li J., Chakrabarty P., Bu B., and Vincent I. (2004) Cyclin-dependent kinase inhibitors attenuate protein hyperphosphorylation, cytoskeletal lesion formation, and motor defects in Niemann-Pick Type C mice. Am. J. Pathol. 165(3), 843-853.
68. Zheng M., Leung C. L., and Liem R. K. (1998) Region-specific expression of cyclin-dependent kinase 5 (cdk5) and its activators, p35 and p39, in the developing and adult rat central nervous system. J. Neurobiol. 35, 141-159.